anaplastic thyroid cancer (aTc) is a rare thyroid tumor associated with high mortality rates; thus, the identification of novel molecular targets and the development of therapeutic strategies are urgently required. The present study aimed to investigate the role of SrY-related HMG box-2 (SoX2) in aTc cells and explore whether the underlying mechanism was associated with fibronectin 1 (FN1). The proliferative, migratory and invasive ability of aTc cell lines was investigated using cell counting Kit-8, colony formation, wound-healing and Transwell assays, respectively; SOX2 expression in FRO cells was knocked down using small interfering rna and SoX2 overexpression in FRO cells was achieved using cDNA constructs; and reverse transcription-quantitative Pcr and western blotting were used to identify the mechanism of action underlying the SoX-2 mediated increased in cell aggressive phenotypes. increased protein expression levels of SoX2 protein were observed in ATC tissue, and FRO and 8505c ATC cell lines. SOX2 overexpression increased the cell viability, and proliferative, migratory and invasive abilities of FRO cell lines. SOX2 overexpression increased FN1, p65, phosphorylated PI3K and AKT expression levels, whereas the knockdown of SOX2 promoted the opposite effects. in conclusion, the present study suggested a possible model of SoX2-mediated gene regulation in aTc cells, in which the overexpression of SoX2 promoted FN1 expression via the PI3K/aKT signaling pathway to induce the aggressive phenotype of ATC. These findings may provide crucial molecular insights into aTc pathogenesis and may demonstrate potential to develop into novel therapeutic interventions for patients with aTc.
Introduction
Thyroid cancer is a common endocrine malignancy, accounting for ~2.1% of all cancers worldwide (1); it includes four major types: Papillary, medullary, follicular and anaplastic thyroid cancer (aTc) (2) . among them, aTc is a rare form of thyroid cancer, comprising <2% of all thyroid cancers, but causing >50% of thyroid-related mortality (3, 4) . Most patients with ATC develop distant metastasis, which often makes traditional treatments ineffective (5) ; thus, there is an urgent requirement for effective diagnostic markers and therapeutic targets.
SrY-related HMG box-2 (SoX2) is a pluripotency-associated transcription factor, which is involved in growth, metastasis, tumorigenicity and drug resistance in multiple different types of cancer (6) ; for example, the expression of SoX2 may be implicated in the metastasis and invasion of pancreatic cancer (7) and gastric and prostatic carcinogenesis (8, 9) . in addition, SoX2 has been observed to promote cell proliferation and tumorigenesis through inducing cell cycle arrest and apoptosis (10) . SoX2 was previously found to be upregulated in aTc tissues, and the inhibition of SoX2 expression improved the sensitivity of aTc cell lines to antitumor drugs (11, 12) . These investigations indicated that SoX2 may be involved in the growth of aTc cells; however, the mechanism remains largely unknown.
Fibronectin 1 (FN1) is an important regulatory factor of cell migration and metastasis, which is reported to be involved in the development of human cutaneous squamous cell carcinoma (13) . FN1 was observed to be upregulated in thyroid cancer, and its silencing inhibited the proliferation, invasion and migration of thyroid cancer, indicating that FN1 may be involved in the development of thyroid cancer (14, 15) . Furthermore, FN1 stimulated cell proliferation and inhibited apoptosis through the activation of PI3K and NF-κB (16) . A previous study demonstrated that SOX2 targeted FN1 and mediated the migration and invasion of SRY-related HMG box-2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway ovarian cancer cells (17); thus, it was hypothesized that SoX2 may also regulate the expression of FN1 to mediate cellular migration and invasion in aTc. The present study aimed to explore the role of SOX2 and FN1 and determine whether SOX2 affected the aggressive phenotype of aTc through affecting FN1 and PI3K/AKT signaling. ). The following primer pairs were used for the qPCR: SOX2 forward, 5'-GTG GAA ACT TTT GTC GGA GAC-3' and reverse, 5'-CGA GTA GGA CAT GCT GTA GGT-3'; and GAPDH forward, 5'-ACA ACT TTG GTA TCG TGG AAG G-3' and reverse, 5'-GCC ATC ACG CCA CAG TTT C-3'. The following thermocycling conditions were used for the qPCR: Initial denaturation at 94˚C for 15 min; 38 cycles at 94˚C for 30 sec, 58˚C for 30 sec and 72˚C for 30 sec; and a final extension at 72˚C for 7 min. SOX2 mRNA expression levels were quantified using the 2 -ΔΔcq method (18) and GaPdH was used as the internal loading control.
Materials and methods
Immunohistochemistry (IHC) analysis. iHc was performed using the standard streptavidin-peroxidase method (19) . Tissue samples were fixed with 10% formalin fixative for 24 h at room temperature, embedded into paraffin and prepared into 4-µm sections. The sections were subsequently deparaffinized in xylene at 92˚C and rehydrated in a descending alcohol series. Following antigen retrieval, endogenous peroxidase activity was blocked using 3% H 2 o 2 for 10 min at 22˚C. Sections were then blocked with 5% goat serum (Thermo Fisher Scientific, inc.) for 1 h at room temperature and subsequently incubated overnight at 4˚C with primary antibodies against SOX2 (1:300; cat. no. sc-365823; Santa Cruz Biotechnology, Inc.). Primary antibodies were substituted with 0.2 mol/l PBS (pH 7.4) for the negative control. Following the primary antibody incubation, the sections were incubated with a biotinylated horse anti-mouse igG secondary antibody (1:100; cat. no. Ba-2001; Vector laboratories; Maravai life Sciences) at room temperature for 30 min, followed by incubation with a streptavidin horseradish peroxidase complex (1:5,000; cat. no. SA-5004; Vector laboratories; Maravai life Sciences) at room temperature for 20 min. Finally, sections were counterstained with hematoxylin for 3 min at room temperature. Chromogen detection was performed using a Tris-Hcl solution containing 0.02% 3,3'-diaminobenzidine (Dako; Agilent Technologies, Inc.) for 5 min at room temperature. Stained tissue was visualized using a light microscope (magnification, x200; Olympus Corporation). Positive staining was defined as >10% of cells appearing as brown granules and was quantified using ImageJ version 1.37 software (National Institutes of Health).
Cell transfection. cell transfection and small interfering (si)rna interference were performed using the lipofectamine ® 2000 Transfection kit (Invitrogen; Thermo Fisher Scientific, Inc.). A total of 4x10 5 FRO cells were seeded into 6-well plates and cultured to 90-95% confluence. A pcDNA3.1 plasmid (4 µg; Invitrogen; Thermo Fisher Scientific, Inc.) carrying a SOX2 cDNA insert (pcDNA3.1-SOX2) was used to construct FRO cells overexpressing SOX2, and the empty pcDNA3.1 (4 µg) plasmid was used as the NC. The amplification of SOX2 expression used the following primers: Forward, 5'-GGA GAC CCA AGC TGG CTA GCA TGT ACA ACA TGA TGG AGA CGG-3' and reverse, 5'-GTT TAA ACG GGC CCT CTA GAT CAC ATG TGT GAG AGG GGC-3' . Genetic knockdown of SOX2 was performed using 2 µg sirna against SoX2 (siSoX2) and 2 µg control non-targeting sirna (sinc) was used as the nc. The sinc sequence was 5'-UUC UCC GAA CGU GUC ACG UTT-3'; and the siSOX2 sequence was 5'-CAG GTT GAT ATC GTT GGT AAT-3'. Cells were transfected for 48 h prior to subsequent experimentation and the overexpression or inhibition of the expression of SoX2 was confirmed using western blotting following transfection. Cell viability and proliferation assays. a total of 1x10 3 FRO cells/well were seeded into a 96-well plate and the cell viability was analyzed using a cell counting Kit-8 (ccK-8; Beyotime institute of Biotechnology) assay, according to the manufacturer's protocol. Cell viability was measured at 48 h post-transfection at an absorbance of 450 nm using a µQuant™ MQX200 microplate reader (Bio-Tek Instruments, Inc.). a colony formation assay was performed based on the standard two-layer soft agar culture to assess proliferation. A total of 500 transfected FRO cells/well were cultured in DMEM in a humidified atmosphere at 37˚C with 5% CO 2 for 12 days. Subsequently, cells were fixed with 1:3 acetic acid methanol at room temperature for 15 min and then stained with 0.1% crystal violet at room temperature for 30 min. The colonies were visualized and manually counted using an Olympus CKX41 light microscope (magnification, x100; olympus corporation).
Wound healing assay. The migratory ability of transfected FRO cells was detected using a wound healing assay. A total of 2x10 5 FRO cells were seeded into a 6-well plate and cultured in serum-free DMEM to ≥95% confluence. A 10-µl pipette tip was used to generate the wound in the monolayer cells and the cells were washed with serum-free medium. at the 0 and 24-h timepoint following wound induction, cells were visualized using an inverted light microscope (magnification, x100; olympus corporation). The relative migratory distance was calculated using the following formula: relative migratory distance (%) = [(width of cell wound at 0 h-width of cell wound at 24 h)/width of cell wound at 0 h] x100.
Matrigel invasion assay. cell invasion was assessed using a Matrigel-coated Transwell chamber (Bd Biosciences), according to the manufacturer's protocol (20) . a total of 1x10 5 transfected FRO cells/well were plated in the upper chambers of Matrigel-coated 8-µm Transwell plates in 100 µl serum-free DMEM and incubated at 37˚C and 5% CO 2 . dMeM supplemented with 10% FBS as a chemoattractant was plated in the lower chambers. Following incubation for 24 h at 37˚C, the non-invasive cells were removed from the upper surface of the Matrigel using a cotton swab. The migratory cells on the underside of the membrane were fixed with cold methanol and acetic acid (3:1 v/v) for 30 min at room temperature and subsequently stained with Giemsa (Sigma-Aldrich; Merck KGaa) at room temperature for 20 min. Stained cells were visualized using a light microscope (magnification, x400; olympus corporation).
Statistical analysis. Statistical analysis was performed using SPSS 22.0 software (iBM corp.) and all data are presented as the mean ± SD of three experimental repeats. Differences between two groups were determined using Student's t-test; differences between multiple groups were determined using one-way ANOVA with Fisher's Least Significant Difference post hoc test. P<0.05 was considered to indicate a statistically signifcant difference.
Results

SOX2 expression levels are increased in ATC tissue and cell lines.
The mRNA expression levels of SOX2 were significantly higher in aTc tissue and cell lines compared with the NC tissue (P<0.01; Fig. 1A ) and Nthy-ori 3-1 cells (P<0.05; Fig. 1B) , respectively. IHC analysis demonstrated that SOX2 protein expression levels were also increased in the aTc tissue compared with the NC tissue (Fig. 1C ). Overall, these results suggested that the expression levels of SoX2 may be increased in aTc, indicating that SoX2 may be involved in the development of aTc.
SOX2 promotes ATC cell viability.
To determine the function of SOX2 in ATC cell lines, SOX2 was knocked down with siRNA or overexpressed using cDNA constructs in the FRO ATC cell line. Western blotting was used to confirm SOX2 expression levels in FRO cells following the transfections; SOX2 expression levels were significantly decreased in cells transfected with siSoX2 compared with the sinc-transfected cells (P<0.01), whereas levels were significantly increased in FRO cells transfected with pcDNA3.1-SOX2 compared with pcDNA3.1 (P<0.01; Fig. 2A) . A CCK-8 assay was performed to evaluate the influence of SOX2 on cell viability. In FRO cells transfected with siSoX2, the viability was significantly decreased compared with cells transfected with sinc (P<0.01; Fig. 2B ). Conversely, the cell viability was significantly increased in cells transfected with pcDNA3.1-SOX2 compared with pcDNA3.1-transfected cells (P<0.05; Fig. 2B ). The effect of SoX2 on cell proliferation was evaluated using a colony formation assay. cells transfected with siSoX2 exhibited a significantly lower proliferative ability compared with siNC-transfected cells (P<0.05; Fig. 2C ), whereas cells transfected with pcDNA3.1-SOX2 demonstrated significantly enhanced proliferative abilities compared with pcDNA3.1-transfected cells (P<0.05; Fig. 2C ). Overall, these results indicated that SoX2 may promote aTc cell proliferation and viability.
SOX2 promotes ATC cell migration and invasion.
The effects of SoX2 on the migratory and invasive abilities of aTc cell lines in vitro were analyzed using wound healing and Matrigel Transwell assays, respectively. siSoX2-transfected cells were observed to have significantly decreased migratory ability compared with sinc-transfected cells, whereas the overexpression of SOX2 with pcDNA3.1-SOX2 significantly enhanced the migratory ability of FRO cells compared with the pcDNA3.1 transfected cells (Fig. 3A) . In addition, the genetic knockdown of SOX2 with siSOX2 significantly inhibited cell invasion compared with sinc-transfected cells, whereas the overexpression of SOX2 with pcDNA3.1-SOX2 significantly increased the invasive ability of FRO cells compared with pcDNA3.1-transfected cells (Fig. 3B) . Overall, these results indicated that SoX2 may promote the migration and invasion of aTc cells.
SOX2 targets FN1 to promote aggressive phenotypes in vitro.
To clarify the possible mechanism of the SoX2-mediated increase in the aggressive phenotypes observed in FRO cells, western blotting was used to assess the effect of SoX2 expression on tumor proliferation-related signaling proteins. siSOX2-transfected cells significantly decreased FN1 and p65 expression levels compared with the sinc group, whereas the overexpression of SOX2 in pcDNA3.1-SOX2 cells significantly increased FN1 and p65 expression levels compared with the pcDNA3.1-transfected cells (Fig. 4) . Similarly, the genetic knockdown of SOX2 in FRO cells significantly decreased the phosphorylation levels of PI3K and AKT compared with siNC-transfected cells, whereas pcDNA3.1-SOX2-transfected cells demonstrated significantly increased phosphorylation levels of PI3K and AKT compared with pcDNA3.1-transfected cells (Fig. 4) . Overall, these results indicated that SOX2 may promote aggressive phenotypes in aTc cell lines by upregulating FN1 expression levels through the activation of the PI3K/aKT signaling pathway.
Discussion
Previous studies have reported that SoX2 expression levels were increased in numerous types of cancer, including glioblastoma, ovarian cancer, small cell lung cancer and squamous cell carcinoma, which affected cancer cell physiology owing to the involvement of SoX2 in numerous protein-protein interactions and complex cell signaling pathways, such as the Hippo, Hedgehog and ras Homolog c/rho-associated Coiled-Protein Kinase signaling pathways (21) (22) (23) (24) . Thus, the pathogenic function of SoX2 in multiple types of cancer is of interest. It is reported that FN1 is a direct target of SOX2 in ovarian cancer cells (17) , however, the role of SoX2 and its relationship with FN1 have not been investigated in ATC. Given that FN1 expression levels were increased in thyroid cancer (15) , it was hypothesized that SOX2 may also regulate the expression of FN1 to mediate the migration and invasion of cells in ATC. Thus, to the best of our knowledge, the present study was the first to focus on the role of SOX2 in aTc cells, including its potential regulatory mechanism. The results demonstrated that SoX2 was overexpressed in aTc tissues and cell lines, which subsequently increased the viability, and proliferative, migratory and invasive ability of aTc cells in vitro. Moreover, SoX2 was found to increase the expression levels of FN1 and other proteins involved in the PI3K/AKT signaling pathway, including p65, PI3K and aKT. These proteins serve important roles in tumorigenesis and regulate critical cellular functions including survival, proliferation, apoptosis and metabolism (25) ; for example, the PI3K/AKT signaling pathway has been implicated in modulating a more aggressive phenotype through regulating cholesterol ester formation in prostate cancer cells (26) ; and PI3K/AKT signaling also been observed to reduce apoptosis, stimulate cell growth and increase proliferation (27) . notably, a previous study also demonstrated that FN1 induced cell proliferation and inhibited apoptosis through the PI3K/AKT signaling pathway (16) . Thus, the present study presented a possible model of SoX2-mediated gene regulation in aTc cell lines, in which the overexpression of SoX2 may promote FN1 expression through the PI3K/AKT signaling pathway to induce the aggressive phenotype of aTc.
SoX2 is a pluripotency-associated transcription factor that induces the proliferation, migration, metastasis and invasion of cancer stem cells through various signaling pathways depending on the cancer type (28) . Previously, the overexpression of SoX2 has been observed in various types of tumor, but it has not been reported in aTc. in the present study, SoX2 was overexpressed in ATC tissue, FRO and 8505c cell lines, which was in agreement with previous studies into other types of cancer (17, 29) . To determine the effect of SoX2 on the aggressive cell phenotype, SoX2 expression was overexpressed using cDNA constructs or knocked down using siRNA in FRO cell lines. The results demonstrated that cell activity, migration and invasion were significantly enhanced by SOX2 overexpression and inhibited by SOX2 knockdown. Therefore, the present study concluded that SoX2 overexpression in aTc may regulate the proliferation, migration and invasion of aTc cells.
FN1 promoted tumor invasion and metastasis through activating specific matrix metalloproteinases (MMPs) in breast cancer (30) . SOX2/FN1 signaling pathway is an important pathway mediating the migration and invasion of ovarian cancer cells; SOX2 directly targeted FN1 to induce the expression of MMP-2 and MMP-9 (17) . In the present study, FN1 expression levels were increased in SoX2-overexpressed cells, and the protein expression levels of tumor proliferation-related signaling pathways, including p65, p-PI3K/PI3K, aKT/p-aKT, were also increased by SoX2. SoX2 induced the activation of AKT and PI3K by phosphorylation, indicating that SOX2 may mediate FN1 upregulation through the activation of the PI3K/AKT signaling pathway. This is similar to a previous study by liao et al (31) , which reported that FN1 stimulated glioma growth, invasion and survival through the activation of the PI3K/AKT signaling pathway. Besides, p65 as a subunit of NF-κB was also upregulated by SoX2; it is widely accepted that NF-κB contributes to the metastasis and invasion of cancer stem cells (32), and it is hypothesized that SOX2 may also mediate FN1 upregulation through activating NF-κB signaling. For example, FN1 was observed to induce an aggressive phenotype following the activation of the NF-κB pathway in nasopharyngeal carcinoma (33) . These results illustrated that the overexpression of SOX2 promoted FN1 expression mainly through the PI3K/AKT/NF-κB signaling pathway, which may induce the aggressive phenotype of aTc.
In conclusion, to the best of our knowledge, this is the first study to report on the function of SOX2 in promoting aggressive phenotypes in aTc and its possible regulatory mechanisms; the present study identified a possible model of SoX2-mediated gene regulation in aTc cell lines. These findings suggested that the observed overexpression of SOX2 in aTc tissues and cell lines may promote the aggressive phenotypes of ATC cells by inducing FN1 expression through the PI3K/AKT signaling pathway. These finding provided crucial molecular insights into aTc pathogenesis and indicated that SoX2 may be useful as a therapeutic target for aTc. investigations on the detailed molecular mechanism of SoX2 in aTc remains to be further researched in the future.
